De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Generic Sweden Toekomstige groei

Future criteriumcontroles 4/6

Generic Sweden zal naar verwachting groeien in winst en omzet met respectievelijk 18% en 13.3% per jaar. De winst per aandeel zal naar verwachting groeien met 17.9% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 53.8% zijn.

Belangrijke informatie

18.0%

Groei van de winst

17.9%

Groei van de winst per aandeel

IT winstgroei	21.8%
Inkomstengroei	13.3%
Toekomstig rendement op eigen vermogen	53.8%
Dekking van analisten	Low
Laatst bijgewerkt	22 Aug 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

We Ran A Stock Scan For Earnings Growth And Generic Sweden (STO:GENI) Passed With Ease

Aug 26

A Look At The Intrinsic Value Of Generic Sweden AB (STO:GENI)

Apr 28

Is It Time To Consider Buying Generic Sweden AB (STO:GENI)?

Apr 08

Is Now The Time To Put Generic Sweden (STO:GENI) On Your Watchlist?

Feb 18

Calculating The Fair Value Of Generic Sweden AB (STO:GENI)

Jan 10

With EPS Growth And More, Generic Sweden (STO:GENI) Is Interesting

Nov 08

Here's Why I Think Generic Sweden (STO:GENI) Is An Interesting Stock

Jul 17

Here's Why I Think Generic Sweden (STO:GENI) Might Deserve Your Attention Today

Apr 13

Is Generic Sweden AB (STO:GENI) A Smart Pick For Income Investors?

Mar 26

A Look At The Intrinsic Value Of Generic Sweden AB (STO:GENI)

Mar 04

Should You Take Comfort From Insider Transactions At Generic Sweden AB (STO:GENI)?

Feb 14

Will Weakness in Generic Sweden AB's (STO:GENI) Stock Prove Temporary Given Strong Fundamentals?

Jan 26

Here's Why I Think Generic Sweden (STO:GENI) Might Deserve Your Attention Today

Jan 05

Is There More To The Story Than Generic Sweden's (STO:GENI) Earnings Growth?

Dec 16

Does Generic Sweden AB (STO:GENI) Have A Place In Your Dividend Portfolio?

Nov 25

Winst- en omzetgroeiprognoses

OM:GENI - Toekomstschattingen van analisten en financiële gegevens uit het verleden (SEK Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	223	35	33	34	1
12/31/2025	203	30	31	32	1
12/31/2024	176	24	21	22	1
6/30/2024	159	23	17	18	N/A
3/31/2024	151	23	31	33	N/A
12/31/2023	143	23	20	22	N/A
9/30/2023	139	24	18	22	N/A
6/30/2023	134	23	19	23	N/A
3/31/2023	131	21	9	13	N/A
12/31/2022	128	20	14	17	N/A
9/30/2022	124	19	16	17	N/A
6/30/2022	121	18	17	18	N/A
3/31/2022	120	19	18	19	N/A
12/31/2021	115	18	18	20	N/A
9/30/2021	107	17	16	17	N/A
6/30/2021	100	15	15	16	N/A
3/31/2021	90	13	14	15	N/A
12/31/2020	82	11	12	13	N/A
9/30/2020	78	10	10	11	N/A
6/30/2020	75	10	8	9	N/A
3/31/2020	72	9	7	8	N/A
12/31/2019	70	9	8	9	N/A
9/30/2019	68	9	9	10	N/A
6/30/2019	64	7	10	11	N/A
3/31/2019	62	7	12	13	N/A
12/31/2018	60	6	11	12	N/A
9/30/2018	59	6	5	7	N/A
6/30/2018	57	6	3	5	N/A
3/31/2018	55	5	N/A	0	N/A
12/31/2017	53	4	N/A	1	N/A
9/30/2017	51	2	N/A	0	N/A
6/30/2017	51	2	N/A	2	N/A
3/31/2017	51	3	N/A	5	N/A
12/31/2016	51	3	N/A	6	N/A
9/30/2016	67	4	N/A	8	N/A
6/30/2016	78	4	N/A	7	N/A
3/31/2016	94	5	N/A	7	N/A
12/31/2015	110	5	N/A	8	N/A
9/30/2015	111	4	N/A	9	N/A
6/30/2015	113	5	N/A	9	N/A
3/31/2015	111	4	N/A	7	N/A
12/31/2014	110	2	N/A	4	N/A
9/30/2014	106	-11	N/A	5	N/A
6/30/2014	105	-11	N/A	5	N/A
3/31/2014	108	-10	N/A	4	N/A
12/31/2013	116	-9	N/A	9	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei GENI ( 18% per jaar) ligt boven de spaarquote ( 1.1% ).

Winst versus markt: De winst van GENI ( 18% per jaar) zal naar verwachting sneller groeien dan de Swedish markt ( 15.2% per jaar).

Hoge groeiwinsten: De winst van GENI zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van GENI ( 13.3% per jaar) zal naar verwachting sneller groeien dan de markt Swedish ( 1.4% per jaar).

Hoge groei-inkomsten: De omzet van GENI ( 13.3% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen GENI zal naar verwachting over 3 jaar zeer hoog zijn ( 53.8 %).

Generic Sweden Toekomstige groei

Future criteriumcontroles 4/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Generic Sweden's (STO:GENI) Profits May Not Reveal Underlying Issues

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 24% undervalued after recent price drop

Now 23% undervalued after recent price drop

Now 20% undervalued

First quarter 2024 earnings: Revenues exceed analyst expectations

Now 23% undervalued

Upcoming dividend of kr1.50 per share

Now 23% undervalued after recent price drop

Some Confidence Is Lacking In Generic Sweden AB (STO:GENI) As Shares Slide 29%

Generic Sweden's (STO:GENI) Solid Earnings May Rest On Weak Foundations

Do Generic Sweden's (STO:GENI) Earnings Warrant Your Attention?

Full year 2023 earnings: EPS misses analyst expectations

Investor sentiment deteriorates as stock falls 16%

Now 25% undervalued

Should You Investigate Generic Sweden AB (STO:GENI) At kr60.20?

Investor sentiment improves as stock rises 16%

Now 22% undervalued

Third quarter 2023 earnings: Revenues exceed analyst expectations

Investor sentiment improves as stock rises 21%

Is Now The Time To Look At Buying Generic Sweden AB (STO:GENI)?

New major risk - Earnings quality

Investor sentiment improves as stock rises 17%

Should You Be Adding Generic Sweden (STO:GENI) To Your Watchlist Today?

Upcoming dividend of kr1.25 per share at 2.9% yield

Full year 2022 earnings: EPS exceeds analyst expectations

Investor sentiment improves as stock rises 21%

Full year 2022 earnings: EPS exceeds analyst expectations

Is Generic Sweden AB (STO:GENI) Potentially Undervalued?

Now 21% undervalued

Now 21% undervalued

Third quarter 2022 earnings: Revenues exceed analyst expectations

Investor sentiment improved over the past week

Second quarter 2022 earnings: Revenues miss analyst expectations

We Ran A Stock Scan For Earnings Growth And Generic Sweden (STO:GENI) Passed With Ease

Investor sentiment deteriorated over the past week

Now 23% undervalued after recent price drop

First quarter 2022 earnings: Revenues miss analyst expectations

Upcoming dividend of kr1.00 per share

A Look At The Intrinsic Value Of Generic Sweden AB (STO:GENI)

Less than half of directors are independent

Is It Time To Consider Buying Generic Sweden AB (STO:GENI)?

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Now 23% undervalued after recent price drop

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorated over the past week

Is Now The Time To Put Generic Sweden (STO:GENI) On Your Watchlist?

Investor sentiment improved over the past week

Calculating The Fair Value Of Generic Sweden AB (STO:GENI)

Investor sentiment deteriorated over the past week

Owner & Member of the board recently sold kr3.5m worth of stock

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Owner & Member of the board recently sold kr3.1m worth of stock

Third quarter 2021 earnings released

With EPS Growth And More, Generic Sweden (STO:GENI) Is Interesting

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released

Investor sentiment improved over the past week

Here's Why I Think Generic Sweden (STO:GENI) Is An Interesting Stock

Owner & Member of the board recently sold kr1.4m worth of stock

Owner & Member of the board recently sold kr1.3m worth of stock

Investor sentiment improved over the past week

First quarter 2021 earnings released

Upcoming dividend of kr0.80 per share

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Here's Why I Think Generic Sweden (STO:GENI) Might Deserve Your Attention Today

Is Generic Sweden AB (STO:GENI) A Smart Pick For Income Investors?

A Look At The Intrinsic Value Of Generic Sweden AB (STO:GENI)

Should You Take Comfort From Insider Transactions At Generic Sweden AB (STO:GENI)?

Will Weakness in Generic Sweden AB's (STO:GENI) Stock Prove Temporary Given Strong Fundamentals?

Here's Why I Think Generic Sweden (STO:GENI) Might Deserve Your Attention Today